Non-alcoholic steatohepatitis (NASH) is a condition characterized by accumulation of fat, inflammation and injury in liver cells in people who consume little or no alcohol. It is the progressive ...

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the best biotech stocks to invest in now. On June 20, Madrigal ...

Exercise is not only a blanket recommendation for optimal health; its an effective drug-free therapy capable of reversing ...

Fatty liver disease is a common health issue. It is often linked to weight and lifestyle. Early detection is key to prevent ...

Altimmune stock took a huge hit after its liver disease drug, pemvidutide, failed to show strong results in reducing fibrosis ...

Fatty liver is one of the conditions that are being rampantly reported, but the symptoms remain unknown to the patients. The ...

The European Union's drug regulator on Friday recommended conditional authorisation of Madrigal Pharmaceuticals' Rezdiffra, ...

Learn about the best exercise recommended by a leading gastroenterologist to reverse fatty liver disease and improve liver ...

The non-alcoholic steatohepatitis (NASH) clinical trials market is estimated to generate a market size of USD 2.96 billion in ...

Fructose overload can lead to non-alcoholic fatty liver and cirrhosis, warns cardiologist Dr Alok Chopra. He explains how it can even lead to cirrhosis.

Doctors report a rising number of cirrhosis cases in people who don’t drink alcohol. Poor diet, obesity, and a sedentary lifestyle are major causes. Experts warn early detection and lifestyle changes ...